EXHIBIT 11.2 SONUS PHARMACEUTICALS, INC. COMPUTATION OF PRO FORMA NET INCOME (LOSS) PER SHARE
Three Months Ended Six Months Ended June 30, 1995 June 30, 1995 -------------------- -------------------- Net loss . . . . . . . . . . . . . . . . . . . . . . . . . $ (1,624,111) $ (890,983) Add interest on deferred revenue . . . . . . . . . . . . . 35,963 128,502 -------------------- -------------------- $ (1,588,148) $ (762,481) ==================== ==================== Weighted average shares outstanding . . . . . . . . . . . . 1,952,836 1,969,332 Weighted average common shares giving effect to the conversion of preferred stock into common stock for all periods subsequent to issuance . . . . . . . . . . . 2,325,219 2,325,219 Net effect of stock options exercised and stock options and warrants granted during the 12 months prior to the Company's filing of its initial public offering, at less than offering price, calculated using the treasury stock method at the offering price of $7 per share, and treated as outstanding for all periods presented . . 97,196 192,712 Weighted average common shares giving effect to the conversion of the convertible subordinated debenture into common stock using the initial public offering price of $7 per share . . . . . . . . . . . . . . . . . . 462,857 462,857 Weighted average common shares giving effect to the conversion of $3.6 million of deferred revenue from the time of receipt, plus accrued interest at the initial public offering price of $7 per share . . . . . . . . . . 536,334 467,809 -------------------- -------------------- Shares used in computation of pro forma net loss per share . . . . . . . . . . . . . . . . . . . . . . . . . . 5,374,442 5,417,929 ==================== ==================== Pro forma net loss per share . . . . . . . . . . . . . . . $ (0.30) $ (0.14) ==================== ====================